Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant klebsiella pneumoniae bloodstream infections in oxa-48 endemic regions
| dc.contributor.author | Mert, Ali | |
| dc.contributor.author | Derin, Okan | |
| dc.contributor.author | Akalın, Halis | |
| dc.contributor.author | Dumlu, Rıdvan | |
| dc.contributor.author | Gündeş, Sibel | |
| dc.contributor.author | Zengin, Rehile | |
| dc.contributor.author | Ergönül, Önder | |
| dc.date.accessioned | 2025-11-05T05:53:06Z | |
| dc.date.available | 2025-11-05T05:53:06Z | |
| dc.date.issued | 2024 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı | |
| dc.description.abstract | Data in the literature on the use of ceftazidime-avibactam (CAZ-AVI) in carbapenem-resistant Klebsiella pneumoniae bloodstream infections (CRKP-BSIs) are limited especially in OXA-48 (Oxacillinase-48) predominant regions. Our study aimed to evaluate the effect of CAZ-AVI use on outcomes in CRKP-BSIs in Turkey, where OXA-48 is endemic. A multicenter retrospective observational study was conducted between January 2017 and September 2021. The effects of clinical and treatment characteristics on 30-day mortality and relapse in CRKP-BSIs were analyzed. Predictors of outcomes were detected using a Cox regression model. The study enrolled 106 adults with CAZ-AVI-sensitive CRKP-BSIs who received CAZ-AVI for at least 72 h. Patients who received CAZ-AVI as initial therapy had lower mortality rates when compared to those who switched from last resort regimens [14.3% (n = 3/21) vs. 37.7% (n = 32/85), p = 0.04]. In multivariate analysis, older age and severe neutropenia were detected to be associated with higher mortality, significantly. Initiation of CAZ-AVI on the day of blood culture was obtained, was found to be significantly associated with lower mortality (HR: 0.25, CI: 0.07–0.84, p = 0.025). CAZ-AVI monotherapy is an important treatment option for CRKP-BSIs in OXA-48 endemic areas. Early initiation of CAZ-AVI should be preferred rather than switching from a last-resort regimen as it profoundly improves the survival rates. | |
| dc.identifier.citation | Mert, A., Derin, O., Akalın, H., Dumlu, R., Gündeş, S., Zengin, R. ... Ergönül, Ö. (2024). Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant klebsiella pneumoniae bloodstream infections in oxa-48 endemic regions. Scientific Reports, 14(1). http://dx.doi.org/10.1038/s41598-024-77259-z | |
| dc.identifier.doi | 10.1038/s41598-024-77259-z | |
| dc.identifier.issn | 2045-2322 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmid | 39487308 | |
| dc.identifier.scopus | 2-s2.0-85208291818 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | http://dx.doi.org/10.1038/s41598-024-77259-z | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/13154 | |
| dc.identifier.volume | 14 | |
| dc.identifier.wos | WOS:001346703300034 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Mert, Ali | |
| dc.institutionauthor | Dumlu, Rıdvan | |
| dc.institutionauthorid | 0000-0001-8213-6064 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Scientific Reports | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Bloodstream Infections | |
| dc.subject | Carbapenem-Resistant Klebsiella Pneumoniae | |
| dc.subject | Ceftazidime-Avibactam | |
| dc.subject | OXA-48 | |
| dc.subject | OXA-48 Endemic Area | |
| dc.title | Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant klebsiella pneumoniae bloodstream infections in oxa-48 endemic regions | |
| dc.type | Article |
